0914 Merck SGEN
BioCentury & Getty Images


With $1.7B in Merck deals, Seattle Genetics plots broader pipeline

Merck deals give Seattle Genetics $725M in cash, $1B in equity up front

Sep 15, 2020 | 12:29 AM GMT

A pair of deals with Merck on Monday gives Seattle Genetics $1.7 billion in cash before counting any milestones, enough to bring additional cancer programs or ADC technologies into the fold via in-licensing or M&A as it pursues a series of label expansions and

Read the full 786 word article

How to gain access

Continue reading with a
two-week free trial.